Pliant Therapeutics/$PLRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pliant Therapeutics
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Ticker
$PLRX
Sector
Primary listing
Employees
49
Headquarters
Website
PLRX Metrics
BasicAdvanced
$72M
-
-$2.43
1.28
-
Price and volume
Market cap
$72M
Beta
1.28
52-week high
$1.95
52-week low
$1.09
Average daily volume
614K
Financial strength
Current ratio
12.004
Quick ratio
11.718
Long term debt to equity
15.263
Total debt to equity
16.062
Interest coverage (TTM)
-58.65%
Profitability
EBITDA (TTM)
-148.377
Management effectiveness
Return on assets (TTM)
-30.15%
Return on equity (TTM)
-61.55%
Valuation
Price to book
0.4
Price to tangible book (TTM)
0.4
Price to free cash flow (TTM)
-0.558
Free cash flow yield (TTM)
-179.27%
Free cash flow per share (TTM)
-2.097
Growth
Earnings per share change (TTM)
-29.95%
3-year earnings per share growth (CAGR)
-6.05%
What the Analysts think about PLRX
Analyst ratings (Buy, Hold, Sell) for Pliant Therapeutics stock.
PLRX Financial Performance
Revenues and expenses
PLRX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pliant Therapeutics stock?
Pliant Therapeutics (PLRX) has a market cap of $72M as of March 31, 2026.
What is the P/E ratio for Pliant Therapeutics stock?
The price to earnings (P/E) ratio for Pliant Therapeutics (PLRX) stock is 0 as of March 31, 2026.
Does Pliant Therapeutics stock pay dividends?
No, Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders as of March 31, 2026.
When is the next Pliant Therapeutics dividend payment date?
Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Pliant Therapeutics?
Pliant Therapeutics (PLRX) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.